… Initial results from QR-1123 Aurora study in adRP We are pleased to announce an … RNA therapy QR-1123 showed target engagement. ProQR plans to start a Phase 2 study for RHO mediated …
… ProQR update and additional sepofarsen Illuminate trial … and restructuring initiatives: Focus the ultevursen (QR-421a) program for USH2A -mediated Usher syndrome and … with regulatory authorities. Suspend development of QR-1123 for autosomal dominant retinitis pigmentosa and QR-504a …
… Conference call additional sepofarsen analyses and company strategy update Webcast … Wed, 04/13/2022 - 12:00 - Wed, 04/13/2022 - 12:30 ProQR shared additional analyses from the Phase 2/3 Illuminate trial of sepofarsen for LCA10 and provided an update on the company …
… at medical conferences. Sepofarsen for LCA Sepofarsen (QR-110) for CEP290 LCA Download link FFB IS (2022) B Leroy, … Sumaroka A, et al… Ultevursen for RP and Usher Ultevursen (QR-421a) for USH2A RP and Usher syndrome External link … for the treatment of RP due to USH2A pdf , 1.12 MB QR-1123 for RP QR-1123 for RHO RP Download link ARVO (2019) …
The EFF is a growing multiple stakeholder platform for the exchange and sharing of insights and innovations to drive the future of clinical development in inherited retinal diseases. Organized by ProQR
… Top-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290 -mediated LCA10 on track for H1 2022 QR-421a pivotal Sirius and Celeste Phase 2/3 trials in Usher … Initial clinical data from Phase 1/2 Aurora trial of QR-1123 for autosomal dominant retinitis pigmentosa expected in …
… Financial Results Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data … data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic … We are on track to share the first clinical data for QR-1123 for adRP in the second half of the year, as well as an …
… analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps … 2/3 Sirius and Celeste clinical trials of ultevursen (QR-421a) in Usher syndrome and retinitis pigmentosa underway; … by year-end 2022 Repeated dose study planned for QR-1123 for autosomal dominant retinitis pigmentosa and initial …
